NYSE:BALL
NYSE:BALLPackaging

Assessing Ball (BALL) Valuation After Recent Share Price Momentum And Margin Improvement Story

Ball (BALL) shares have attracted renewed attention after recent trading gains, with the stock up about 4% over the past week and about 16% over the past month. This has prompted investors to reassess its valuation and fundamentals. See our latest analysis for Ball. That recent 16.4% 30 day share price return builds on an 18.1% 90 day gain. However, the 1 year total shareholder return of 8.6% and the 5 year total shareholder return of a 34.5% decline show that momentum has been relatively...
NasdaqGS:CPB
NasdaqGS:CPBFood

Does Campbell EVP’s Largest Share Sale Yet Reframe Insider Confidence At Campbell Soup (CPB)?

On December 31, Campbell Soup Company executive vice president Charles A. Brawley III sold 11,550 shares for US$325,075, cutting his direct stake by about 21% amid ongoing volume and margin pressures. This insider sale stands out as his largest open market disposal on record and comes as Campbell continues dividends, buybacks, and reaffirmed full-year guidance despite business headwinds. Next, we’ll examine how this sizable insider share sale by a senior leader may influence Campbell’s...
NasdaqGS:CDW
NasdaqGS:CDWElectronic

Templar Shield–ServiceNow Expansion Might Change The Case For Investing In CDW (CDW)

In early January 2026, Templar Shield and CDW announced a partnership to deliver global risk, security, operational technology, and AI governance solutions on the ServiceNow AI Platform, with Templar Shield operating under CDW’s global contracting model to streamline access for CDW clients. This collaboration materially broadens CDW’s higher-value services capabilities in areas like integrated risk management and AI governance, potentially deepening customer relationships by embedding CDW...
NYSE:FERG
NYSE:FERGTrade Distributors

A Look At Ferguson (FERG) Valuation After Short Interest Drops Below Peer Levels

The recent 14.67% drop in short interest for Ferguson Enterprises (FERG), bringing it to 1.28% of float versus about 6.00% for peers, has put the stock on many investors’ watchlists. See our latest analysis for Ferguson Enterprises. The shift in sentiment is showing up in the price too, with a 4.11% 1-day share price return at $238.86 and a 6.15% year-to-date share price return sitting alongside a 43.08% 1-year total shareholder return, hinting that momentum has been building rather than...
NasdaqGM:AQST
NasdaqGM:AQSTPharmaceuticals

A Look At Aquestive Therapeutics (AQST) Valuation After Anaphylm Regulatory Update And FDA Feedback

Regulatory update on Anaphylm and why it matters for Aquestive Therapeutics (AQST) Aquestive Therapeutics (AQST) recently reported fresh detail on the U.S. regulatory review of its Anaphylm sublingual epinephrine film, highlighting current FDA feedback on application deficiencies and timing risks around the January 31, 2026 PDUFA decision date. See our latest analysis for Aquestive Therapeutics. The Anaphylm update arrived after a sharp reset in sentiment, with a 1-day share price return of...
NasdaqGS:CERT
NasdaqGS:CERTHealthcare Services

Does Leerink’s Upgrade of Certara (CERT) Reveal a Deeper Edge in Biosimulation-Driven Drug Development?

Earlier this week, Leerink Partners upgraded Certara to an “Outperform” rating, highlighting renewed confidence in the company’s biosimulation and technology-enabled drug development services. This shift in analyst sentiment comes after a period of more cautious views, underscoring how differentiated biosimulation capabilities can influence institutional perspectives on Certara’s role in modern drug R&D. Now we’ll examine how Leerink’s upgraded outlook on Certara’s biosimulation franchise...